$VIR
Vir Biotechnology, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022021854 Filed on November 03, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $49.41M $374.6M
YoY Change -93.92% 261.49%
Cost Of Revenue $5.996M $22.25M
YoY Change -89.46% 183.98%
Gross Profit $43.41M $352.3M
YoY Change -94.26% 267.83%
Gross Profit Margin 87.86% 94.06%
Selling, General & Admin $38.74M $43.17M
YoY Change -30.54% -14.5%
% of Gross Profit 89.24% 12.25%
Research & Development $155.2M $114.2M
YoY Change 20.91% 15.71%
% of Gross Profit 357.43% 32.41%
Depreciation & Amortization $1.953M $1.600M
YoY Change 28.4% 14.29%
% of Gross Profit 4.5% 0.45%
Operating Expenses $193.9M $157.3M
YoY Change 5.32% 0.22%
Operating Profit -$150.5M $195.0M
YoY Change -126.32% -465.2%
Interest Expense $25.05M -$4.258M
YoY Change -196.89% -102.6%
% of Operating Profit -2.18%
Other Income/Expense, Net -$26.19M $22.77M
YoY Change 374000.0% -86.13%
Pretax Income -$151.6M $217.7M
YoY Change -127.78% 96.58%
Income Tax -$50.04M $42.42M
% Of Pretax Income 19.48%
Net Earnings -$101.6M $175.3M
YoY Change -119.34% 58.76%
Net Earnings / Revenue -205.63% 46.81%
Basic Earnings Per Share $1.32
Diluted Earnings Per Share -$0.76 $1.30
COMMON SHARES
Basic Shares Outstanding 133.1M 132.7M
Diluted Shares Outstanding 135.0M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.402B $2.346B
YoY Change 239.2% 149.77%
Cash & Equivalents $848.6M $963.7M
Short-Term Investments $1.553B $1.383B
Other Short-Term Assets $26.40M $67.14M
YoY Change -67.65% 98.13%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00
Other Receivables $0.00 $0.00
Total Short-Term Assets $2.519B $2.414B
YoY Change 61.19% 126.35%
LONG-TERM ASSETS
Property, Plant & Equipment $105.6M $100.2M
YoY Change 146.55% 276.65%
Goodwill $16.90M $16.94M
YoY Change -0.22% 0.0%
Intangibles $32.76M $32.89M
YoY Change -1.6% -1.59%
Long-Term Investments $23.93M $34.10M
YoY Change -88.12%
Other Assets $21.23M $13.49M
YoY Change 117.01% 44.35%
Total Long-Term Assets $283.0M $282.4M
YoY Change -27.7% 96.25%
TOTAL ASSETS
Total Short-Term Assets $2.519B $2.414B
Total Long-Term Assets $283.0M $282.4M
Total Assets $2.802B $2.696B
YoY Change 43.38% 122.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.422M $2.722M
YoY Change -1.52% -35.57%
Accrued Expenses $489.1M $282.6M
YoY Change 245.62% 335.83%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $511.0M $308.2M
YoY Change 49.76% 31.87%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.862M $7.166M
YoY Change 209.53% 87.44%
Total Long-Term Liabilities $7.862M $7.166M
YoY Change 209.53% 87.44%
TOTAL LIABILITIES
Total Short-Term Liabilities $511.0M $308.2M
Total Long-Term Liabilities $7.862M $7.166M
Total Liabilities $724.1M $546.1M
YoY Change 38.61% 63.54%
SHAREHOLDERS EQUITY
Retained Earnings $377.2M $478.8M
YoY Change -372.15% -172.12%
Common Stock $13.00K $13.00K
YoY Change 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.078B $2.150B
YoY Change
Total Liabilities & Shareholders Equity $2.802B $2.696B
YoY Change 43.38% 122.77%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$101.6M $175.3M
YoY Change -119.34% 58.76%
Depreciation, Depletion And Amortization $1.953M $1.600M
YoY Change 28.4% 14.29%
Cash From Operating Activities $35.13M $117.9M
YoY Change 356.48% -211.42%
INVESTING ACTIVITIES
Capital Expenditures $12.60M -$18.99M
YoY Change -196.4% 216.23%
Acquisitions
YoY Change
Other Investing Activities -$140.5M -$643.6M
YoY Change -61.44% -905.87%
Cash From Investing Activities -$153.1M -$662.6M
YoY Change -59.44% -997.12%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 2.011M 1.985M
YoY Change -64.53% -45.3%
NET CHANGE
Cash From Operating Activities 35.13M 117.9M
Cash From Investing Activities -153.1M -662.6M
Cash From Financing Activities 2.011M 1.985M
Net Change In Cash -116.0M -542.7M
YoY Change -68.15% 1816.04%
FREE CASH FLOW
Cash From Operating Activities $35.13M $117.9M
Capital Expenditures $12.60M -$18.99M
Free Cash Flow $22.53M $136.9M
YoY Change 8.52% -237.16%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
vir Non Cash Common Stock Issued For Contingent Consideration
NonCashCommonStockIssuedForContingentConsideration
1860000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6413000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
4191000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
583000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3969000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
90000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
73003000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
2413616000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
1562821000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
32888000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
33287000
CY2022Q3 us-gaap Goodwill
Goodwill
16937000
CY2021Q4 us-gaap Goodwill
Goodwill
16937000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
100226000
us-gaap Financing Receivable Accrued Interest Writeoff
FinancingReceivableAccruedInterestWriteoff
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42834000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84716000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
87220000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7276000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7006000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
34102000
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
201388000
CY2022Q3 us-gaap Other Assets
OtherAssets
6209000
CY2021Q4 us-gaap Other Assets
OtherAssets
2775000
CY2022Q3 us-gaap Assets
Assets
2695970000
CY2021Q4 us-gaap Assets
Assets
1954268000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2722000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
6521000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
282616000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
CY2022Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2022#AccruedLiabilitiesAndOtherLiabilities
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
dei Entity Central Index Key
EntityCentralIndexKey
0001706431
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39083
dei Entity Registrant Name
EntityRegistrantName
Vir Biotechnology, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-2730369
dei Entity Address Address Line1
EntityAddressAddressLine1
499 Illinois Street
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 500
dei Entity Address City Or Town
EntityAddressCityOrTown
San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94158
dei City Area Code
CityAreaCode
415
dei Local Phone Number
LocalPhoneNumber
906-4324
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
VIR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q3 vir Equity Investment Current
EquityInvestmentCurrent
22801000
CY2021Q4 vir Equity Investment Current
EquityInvestmentCurrent
143148000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
133115621
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
963735000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
54180000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
347815000
CY2022Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
1359945000
CY2021Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
217182000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
12955000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
8594000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
773079000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
236512000
CY2022Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
22865000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
98209000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
308203000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
341242000
CY2022Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
54653000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
3815000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
126942000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
133561000
CY2022Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
30712000
CY2021Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
22822000
CY2022Q3 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
18439000
CY2021Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
18439000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
7166000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
2540000
CY2022Q3 us-gaap Liabilities
Liabilities
546115000
CY2021Q4 us-gaap Liabilities
Liabilities
522419000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
133027358
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
133027358
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131161404
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131161404
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
13000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1682882000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1571535000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-11880000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1099000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
478840000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138600000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2149855000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1431849000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
2695970000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1954268000
CY2022Q3 us-gaap Revenues
Revenues
374557000
CY2021Q3 us-gaap Revenues
Revenues
103616000
us-gaap Revenues
Revenues
1566387000
us-gaap Revenues
Revenues
282668000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
22253000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
7836000
us-gaap Cost Of Revenue
CostOfRevenue
140323000
us-gaap Cost Of Revenue
CostOfRevenue
8988000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
114166000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
98669000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
319475000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
319665000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
43174000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
50496000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
123019000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
105016000
CY2022Q3 us-gaap Costs And Expenses
CostsAndExpenses
179593000
CY2021Q3 us-gaap Costs And Expenses
CostsAndExpenses
157001000
us-gaap Costs And Expenses
CostsAndExpenses
582817000
us-gaap Costs And Expenses
CostsAndExpenses
433669000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
194964000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-53385000
us-gaap Operating Income Loss
OperatingIncomeLoss
983570000
us-gaap Operating Income Loss
OperatingIncomeLoss
-151001000
CY2022Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-13590000
CY2021Q3 us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
164072000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
-120019000
us-gaap Equity Securities Fv Ni Unrealized Gain Loss
EquitySecuritiesFvNiUnrealizedGainLoss
164072000
CY2022Q3 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
9332000
CY2021Q3 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
11000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
11920000
us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
272000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
27026000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
64000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
30447000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9430000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
22768000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
164147000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-77652000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
154914000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
217732000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
110762000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
905918000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3913000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42420000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
334000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
288478000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
583000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
175312000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
110428000
us-gaap Net Income Loss
NetIncomeLoss
617440000
us-gaap Net Income Loss
NetIncomeLoss
3330000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.32
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.30
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132729530
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130665831
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132422028
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
129520837
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134963317
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133854419
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134711777
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133318979
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
175312000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
110428000
us-gaap Net Income Loss
NetIncomeLoss
617440000
us-gaap Net Income Loss
NetIncomeLoss
3330000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-4318000
CY2021Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
13000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-10754000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-71000
CY2022Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
9000
CY2021Q3 us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
-14000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
27000
us-gaap Other Comprehensive Income Loss Reclassification Adjustment From Aoci Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax
OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
-42000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4327000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
27000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10781000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-29000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
170985000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
110455000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
606659000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
3301000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
1952012000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
2044000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
24814000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-4327000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
175312000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2149855000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
737325000
CY2021Q3 vir Stock Issued During Period Value Issued For Settlement Of Contingent Consideration
StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration
1860000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3690000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
22944000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
27000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
110428000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
876274000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
1431849000
vir Stock Issued During Period Value Collaboration Agreement
StockIssuedDuringPeriodValueCollaborationAgreement
28462000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3602000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
2066000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
77217000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-10781000
us-gaap Net Income Loss
NetIncomeLoss
617440000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
2149855000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
716852000
vir Stock Issued During Period Value Collaboration Agreement
StockIssuedDuringPeriodValueCollaborationAgreement
85213000
vir Stock Issued During Period Value Issued For Settlement Of Contingent Consideration
StockIssuedDuringPeriodValueIssuedForSettlementOfContingentConsideration
1860000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
9635000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
59413000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-29000
us-gaap Net Income Loss
NetIncomeLoss
3330000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
876274000
us-gaap Profit Loss
ProfitLoss
617440000
us-gaap Profit Loss
ProfitLoss
3330000
vir Change In Estimated Constraint On Profit Sharing Amount
ChangeInEstimatedConstraintOnProfitSharingAmount
353526000
vir Change In Estimated Constraint On Profit Sharing Amount
ChangeInEstimatedConstraintOnProfitSharingAmount
0
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4431000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3891000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
399000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
399000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1315000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
859000
vir Noncash Lease Expense
NoncashLeaseExpense
6473000
vir Noncash Lease Expense
NoncashLeaseExpense
4471000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
120019000
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
-164072000
vir Change In Estimated Fair Value Of Contingent Consideration
ChangeInEstimatedFairValueOfContingentConsideration
7890000
vir Change In Estimated Fair Value Of Contingent Consideration
ChangeInEstimatedFairValueOfContingentConsideration
63246000
vir Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value
IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
-93803000
vir Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value
IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
-8140000
us-gaap Share Based Compensation
ShareBasedCompensation
77217000
us-gaap Share Based Compensation
ShareBasedCompensation
59413000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
301000
us-gaap Other Operating Activities Cash Flow Statement
OtherOperatingActivitiesCashFlowStatement
486000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-491872000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
93003000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-11023000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1878000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
3434000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
1051000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2003000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-959000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
65144000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-13490000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-2547000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-383000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-24506000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
89559000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1628127000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-55284000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
22000
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
55432000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
8750000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
1069752000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
55729000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
84836000
us-gaap Proceeds From Sale Maturity And Collections Of Investments
ProceedsFromSaleMaturityAndCollectionsOfInvestments
301243000
vir Proceeds From Disposal Of An Equipment
ProceedsFromDisposalOfAnEquipment
0
vir Proceeds From Disposal Of An Equipment
ProceedsFromDisposalOfAnEquipment
4000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1040326000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
236768000
vir Proceeds From Issuance Of Common Stock In Connection With A Grant Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement
28462000
vir Proceeds From Issuance Of Common Stock In Connection With A Grant Agreement
ProceedsFromIssuanceOfCommonStockInConnectionWithAGrantAgreement
0
vir Proceeds From Issuance Of Common Stock In Connection With Collaboration
ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
0
vir Proceeds From Issuance Of Common Stock In Connection With Collaboration
ProceedsFromIssuanceOfCommonStockInConnectionWithCollaboration
85213000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
183000
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
187000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3602000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
9635000
us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
2066000
vir Payment Of Contingent Consideration
PaymentOfContingentConsideration
1197000
vir Payment Of Contingent Consideration
PaymentOfContingentConsideration
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
32750000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
94661000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
620551000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
276145000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
363415000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
451487000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
983966000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
727632000
vir Non Cash Common Stock Issued For Contingent Consideration
NonCashCommonStockIssuedForContingentConsideration
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
191653000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
963735000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
714521000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
12955000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents At Carrying Value
RestrictedCashAndCashEquivalentsAtCarryingValue
6112000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
7276000
CY2021Q3 us-gaap Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
6999000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
983966000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
727632000
CY2020Q4 vir Sale Of Stock Consideration Aggregate Offering Price
SaleOfStockConsiderationAggregateOfferingPrice
300000000.0
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
478800000
CY2022Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
2400000000
CY2022Q3 vir Cash Cash Equivalents And Short Term Investments Excluding Equity Investment
CashCashEquivalentsAndShortTermInvestmentsExcludingEquityInvestment
2400000000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span>
CY2022Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
CY2021Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss
DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
0
us-gaap Derivatives Embedded Derivatives
DerivativesEmbeddedDerivatives
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Embedded Derivatives</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the unaudited condensed consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the unaudited condensed consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the unaudited condensed consolidated statements of operations based on the nature of the related contingencies.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Changes in fair values of embedded derivatives related to the achievement of various milestones for product candidates are recorded within research and development expenses or selling, general and administrative expenses based on the nature of the relevant underlying activities. Otherwise, changes in fair values are recorded within other income (expense), net.</span></p>
CY2022Q3 vir Financial Assets Amortized Cost Basis
FinancialAssetsAmortizedCostBasis
2364039000
CY2022Q3 vir Financial Assets Gross Unrealized Holding Gains
FinancialAssetsGrossUnrealizedHoldingGains
0
CY2022Q3 vir Financial Assets Gross Unrealized Holding Losses
FinancialAssetsGrossUnrealizedHoldingLosses
11626000
CY2022Q3 vir Financial Assets Fair Value
FinancialAssetsFairValue
2352413000
CY2021Q4 vir Financial Assets Amortized Cost Basis
FinancialAssetsAmortizedCostBasis
764540000
CY2021Q4 vir Financial Assets Gross Unrealized Holding Gains
FinancialAssetsGrossUnrealizedHoldingGains
0
CY2021Q4 vir Financial Assets Gross Unrealized Holding Losses
FinancialAssetsGrossUnrealizedHoldingLosses
872000
CY2021Q4 vir Financial Assets Fair Value
FinancialAssetsFairValue
763668000
CY2022Q3 us-gaap Interest Receivable
InterestReceivable
2800000
us-gaap Financing Receivable Accrued Interest Writeoff
FinancingReceivableAccruedInterestWriteoff
0
us-gaap Debt Securities Available For Sale Unrealized Gain Loss
DebtSecuritiesAvailableForSaleUnrealizedGainLoss
11600000
CY2022Q2 vir Adjustments To Profit Sharing Amounts
AdjustmentsToProfitSharingAmounts
20400000
CY2022Q3 vir Profit Sharing Amount
ProfitSharingAmount
291226000
CY2021Q3 vir Profit Sharing Amount
ProfitSharingAmount
102398000
vir Profit Sharing Amount
ProfitSharingAmount
1863374000
vir Profit Sharing Amount
ProfitSharingAmount
107731000
CY2022Q3 vir Profit Sharing Amount Constrained
ProfitSharingAmountConstrained
-2431000
CY2021Q3 vir Profit Sharing Amount Constrained
ProfitSharingAmountConstrained
0
vir Profit Sharing Amount Constrained
ProfitSharingAmountConstrained
-399864000
vir Profit Sharing Amount Constrained
ProfitSharingAmountConstrained
0
CY2022Q3 vir Profit Sharing Amount Previously Constrained Released
ProfitSharingAmountPreviouslyConstrainedReleased
20350000
CY2021Q3 vir Profit Sharing Amount Previously Constrained Released
ProfitSharingAmountPreviouslyConstrainedReleased
0
vir Profit Sharing Amount Previously Constrained Released
ProfitSharingAmountPreviouslyConstrainedReleased
20350000
vir Profit Sharing Amount Previously Constrained Released
ProfitSharingAmountPreviouslyConstrainedReleased
0
CY2022Q3 vir Totalcollaboration Revenue
TotalcollaborationRevenue
309145000
CY2021Q3 vir Totalcollaboration Revenue
TotalcollaborationRevenue
102398000
vir Totalcollaboration Revenue
TotalcollaborationRevenue
1483860000
vir Totalcollaboration Revenue
TotalcollaborationRevenue
107731000
CY2022Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
119150000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
57326000
CY2022Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
18924000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
14492000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
100226000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
42834000
CY2022Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1600000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
4400000
CY2021Q3 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1400000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
3900000
CY2022Q3 vir Milestone Payable
MilestonePayable
0
CY2021Q4 vir Milestone Payable
MilestonePayable
95000000
CY2022Q3 vir Profit Share Amount Constraint
ProfitShareAmountConstraint
61684000
CY2021Q4 vir Profit Share Amount Constraint
ProfitShareAmountConstraint
0
CY2022Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
98189000
CY2021Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
6217000
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
27771000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
58672000
CY2022Q3 vir Research And Development Expenses Current
ResearchAndDevelopmentExpensesCurrent
40116000
CY2021Q4 vir Research And Development Expenses Current
ResearchAndDevelopmentExpensesCurrent
28073000
CY2022Q3 vir Payroll And Related Expenses Current
PayrollAndRelatedExpensesCurrent
23714000
CY2021Q4 vir Payroll And Related Expenses Current
PayrollAndRelatedExpensesCurrent
29753000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5633000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2791000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4115000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3927000
CY2022Q3 vir Excess Funds Payable Under Grant Agreements Current
ExcessFundsPayableUnderGrantAgreementsCurrent
0
CY2021Q4 vir Excess Funds Payable Under Grant Agreements Current
ExcessFundsPayableUnderGrantAgreementsCurrent
1825000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
21394000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
10254000
CY2022Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
282616000
CY2021Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
236512000
vir Lease Arrangement Contractual Expiration Beginning Year
LeaseArrangementContractualExpirationBeginningYear
2022
vir Lease Arrangement Contractual Expiration Ending Year
LeaseArrangementContractualExpirationEndingYear
2033
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years.
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
4846000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
19408000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
18567000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
16259000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
16703000
CY2022Q3 vir Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
103855000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
179638000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
40108000
CY2022Q3 vir Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received
LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived
26670000
CY2022Q3 vir Present Value Of Operating Lease Liabilities
PresentValueOfOperatingLeaseLiabilities
112860000
CY2022Q3 vir Operating Lease Incentive Over Lease Liabilities
OperatingLeaseIncentiveOverLeaseLiabilities
18197000
CY2021Q4 vir Operating Lease Incentive Over Lease Liabilities
OperatingLeaseIncentiveOverLeaseLiabilities
49536000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
84716000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
87220000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
4115000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
3927000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
126942000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
133561000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
131057000
CY2021Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
137488000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
129520837
CY2022Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2144302
CY2021Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3173930
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2227493
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
3757681
CY2022Q3 vir Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
75759
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.106
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.108
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.069
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.115
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.038
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.112
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.031
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.115
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.030
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.008
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.010
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.016
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.006
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.012
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
24814000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
22944000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
77217000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
59413000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
175312000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
110428000
us-gaap Net Income Loss
NetIncomeLoss
617440000
us-gaap Net Income Loss
NetIncomeLoss
3330000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132729530
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
130665831
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
132422028
CY2021Q3 vir Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
14658
vir Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
55080
vir Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting
IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
36138
CY2022Q3 vir Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan
13726
CY2021Q3 vir Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan
0
vir Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan
7176
vir Incremental Common Shares Attributableto Share Based Payment Arrangements Employee Stock Purchase Plan
IncrementalCommonSharesAttributabletoShareBasedPaymentArrangementsEmployeeStockPurchasePlan
0
CY2022Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0
CY2021Q3 us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
0
us-gaap Incremental Common Shares Attributable To Contingently Issuable Shares
IncrementalCommonSharesAttributableToContingentlyIssuableShares
4323
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134963317
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133854419
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
134711777
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
133318979
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.32
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.85
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
4.66
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.30
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.82
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
4.58
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.02
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10575325
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7383338
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
11438772
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6303487
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
217732000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
110762000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
905918000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
3913000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
42420000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
334000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
288478000
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.195
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.003
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.318
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.149
CY2022Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
10500000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
7400000

Files In Submission

Name View Source Status
0000950170-22-021854-index-headers.html Edgar Link pending
0000950170-22-021854-index.html Edgar Link pending
0000950170-22-021854.txt Edgar Link pending
0000950170-22-021854-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
vir-20220930.htm Edgar Link pending
vir-20220930.xsd Edgar Link pending
vir-ex31_1.htm Edgar Link pending
vir-ex31_2.htm Edgar Link pending
vir-ex32_1.htm Edgar Link pending
vir-20220930_def.xml Edgar Link unprocessable
vir-20220930_cal.xml Edgar Link unprocessable
vir-20220930_lab.xml Edgar Link unprocessable
vir-20220930_pre.xml Edgar Link unprocessable
vir-20220930_htm.xml Edgar Link completed
FilingSummary.xml Edgar Link unprocessable